Day One Biopharmaceuticals reports Q2 EPS (29c), consensus (34c)

Reports Q2 revenue $33.91M, consensus $34.9M. “We have strong momentum going into the second half of 2025. We continue to focus on our three core priorities: accelerating revenue growth with OJEMDA, advancing our pipeline, and pursuing value-driving portfolio expansion anchored in financial discipline,” said Jeremy Bender, chief executive officer of Day One. “With strong execution across the organization and a solid financial foundation, we’re building a company that aims to deliver meaningful value to patients and to shareholders.”